A Phase 3 interventional study of Apalutamide and Abiraterone acetate in Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals, Inc.. Active, not recruiting at 173 sites in 16 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 16 in phase 3, reaches primary completion later than 2 of the 35 other live ones, and was the 7th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Marco Oderda · Sites in Italy
Ages 18–80 · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 16 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 982 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 70 interventional studies. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aragon Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Aragon Pharmaceuticals, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 8th largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2014, is one of 15 in phase 3, reaches primary completion later than 2 of the 22 other live ones, and was the 44th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
9 of the studies testing apalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT06067269Jonsson Comprehensive Cancer CenterHormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).
This is a randomized (study drug assigned by chance), double-blind (neither the Investigator nor the participant know the treatment) placebo-controlled and multicenter (when more than 1 hospital or medical school team work on a medical research study) study to determine if participants with chemotherapy-naive mCRPC will benefit from the addition of apalutamide to AAP compared with AAP alone. The study consists of 3 phases: Screening phase; Treatment phase, and Follow-up phase. At the final analysis, the study will be unblinded. After the Independent Data Monitoring Committee (IDMC) review and the sponsor's subsequent decision participants will be offered to receive treatment either in the Open-Label Extension Phase or the Long-Term Extension Phase of study. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive apalutamide 240 milligram (mg) (4\*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4\*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).
Drug: Apalutamide · Drug: Abiraterone acetate · Drug: Prednisone
Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4\*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).
Drug: Abiraterone acetate · Drug: Prednisone · Drug: Placebo
Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.
Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.
Also known as: ZYTIGA
Participants will receive 5 mg tablet of prednisone twice daily orally.
Participants will receive matching placebo to apalutamide once daily orally.
Radiographic Progression-free Survival (rPFS)
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Time frame: Up to 3 years and 4 months
Overall Survival (OS)
The OS was defined as the time from randomization to date of death from any cause.
Time frame: Up to 5 years and 10 months
Time to Chronic Opioid Use
Time to chronic opioid use was defined as the time from date of randomization to the first date of opioid use.
Time frame: Up to 5 years and 10 months
Time to Initiation of Cytotoxic Chemotherapy
Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy.
Time frame: Up to 5 years and 10 months
Time to Pain Progression
Time to pain progression: time from randomization to first date that participant either experienced an increase by 2 points from baseline in Brief Pain Inventory Short Form (BPI-SF) worst pain intensity item (item 3) or Case Report Form (CRF) pain, observed at 2 consecutive evaluations \>=4 wks apart, or initiation of chronic opioids as defined in time to chronic opioid use, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3(worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." A lower score is better.CRF pain refers to participant's response to global pain assessment "How would you rate your pain over the past 7 days?"with a scale of 0("No pain") to 10("Pain as bad as you can imagine"),that is systematically reported and recorded on the eCRF.
Time frame: Up to 5 years and 10 months
| Milestone | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone |
|---|---|---|
| Started | 490 | 492 |
| Completed | 39 | 45 |
| Not completed | 451 | 447 |
| Withdrew: Progressive disease | 365 | 327 |
| Withdrew: Adverse event | 45 | 56 |
| Withdrew: Withdrawal by subject | 21 | 38 |
| Withdrew: Death | 11 | 6 |
| Withdrew: Physician decision | 5 | 9 |
| Withdrew: Non-compliance with study drug | 1 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Other | 1 | 7 |
| Withdrew: Randomized, not treated | 1 | 2 |
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
| months | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone |
|---|---|---|
| Radiographic Progression-free Survival (rPFS) | 16.59 (13.86 to 19.32) | 23.98 (19.71 to 27.50) |
The OS was defined as the time from randomization to date of death from any cause.
| months | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone |
|---|---|---|
| Overall Survival (OS) | 33.71 (31.24 to 38.28) | 36.17 (32.76 to 38.77) |
Time to chronic opioid use was defined as the time from date of randomization to the first date of opioid use.
| months | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone |
|---|---|---|
| Time to Chronic Opioid Use | 53.26 (42.02 to NA) | 46.98 (39.23 to NA) |
Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy.
| months | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone |
|---|---|---|
| Time to Initiation of Cytotoxic Chemotherapy | 34.23 (29.54 to 39.16) | 36.11 (32.23 to 42.55) |
Time to pain progression: time from randomization to first date that participant either experienced an increase by 2 points from baseline in Brief Pain Inventory Short Form (BPI-SF) worst pain intensity item (item 3) or Case Report Form (CRF) pain, observed at 2 consecutive evaluations \>=4 wks apart, or initiation of chronic opioids as defined in time to chronic opioid use, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3(worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." A lower score is better.CRF pain refers to participant's response to global pain assessment "How would you rate your pain over the past 7 days?"with a scale of 0("No pain") to 10("Pain as bad as you can imagine"),that is systematically reported and recorded on the eCRF.
| months | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone |
|---|---|---|
| Time to Pain Progression | 26.51 (22.57 to 29.50) | 21.82 (17.97 to 25.66) |
Collected over Up to 3 years and 4 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo+ Abiraterone Acetate - Prednisolone | 350/489 (71.6%) | 166/489 (33.9%) | 459/489 (93.9%) |
| Apalutamide + Abiraterone Acetate - Prednisolone | 338/490 (69%) | 192/490 (39.2%) | 472/490 (96.3%) |
| Event | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone |
|---|---|---|
| PneumoniaInfections and infestations | 10/489 | 18/490 |
| HaematuriaRenal and urinary disorders | 13/489 | 6/490 |
| Urinary Tract InfectionInfections and infestations | 7/489 | 12/490 |
| Back PainMusculoskeletal and connective tissue disorders | 8/489 | 4/490 |
| FallInjury, poisoning and procedural complications | 1/489 | 8/490 |
| SepsisInfections and infestations | 7/489 | 5/490 |
| Acute Kidney InjuryRenal and urinary disorders | 7/489 | 6/490 |
| Atrial FibrillationCardiac disorders | 6/489 | 3/490 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 6/489 | 1/490 |
| Myocardial InfarctionCardiac disorders | 1/489 | 6/490 |
| Event | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone |
|---|---|---|
| FatigueGeneral disorders | 134/489 | 164/490 |
| Back PainMusculoskeletal and connective tissue disorders | 133/489 | 154/490 |
| HypertensionVascular disorders | 122/489 | 144/490 |
| Weight DecreasedInvestigations | 84/489 | 136/490 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 121/489 | 127/490 |
| FallInjury, poisoning and procedural complications | 92/489 | 106/490 |
| ConstipationGastrointestinal disorders | 94/489 | 96/490 |
| DiarrhoeaGastrointestinal disorders | 73/489 | 91/490 |
| NauseaGastrointestinal disorders | 76/489 | 84/490 |
| HypokalaemiaMetabolism and nutrition disorders | 73/489 | 79/490 |
| Age, Continuous(years) | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone | Total |
|---|---|---|---|
| Mean | 70.7 ± 8.06 | 71.4 ± 8.34 | 71.1 ± 8.21 |
| Sex: Female, Male(Participants) | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 490 | 492 | 982 |
| Ethnicity (NIH/OMB)(Participants) | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone | Total |
|---|---|---|---|
| Hispanic or Latino | 54 | 50 | 104 |
| Not Hispanic or Latino | 411 | 422 | 833 |
| Unknown or Not Reported | 25 | 20 | 45 |
| Race/Ethnicity, Customized(Participants) | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 8 | 9 | 17 |
| Asian | 53 | 58 | 111 |
| Black or African American | 18 | 19 | 37 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 373 | 365 | 738 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 20 | 20 | 40 |
| Other | 18 | 21 | 39 |
| Region of Enrollment(Participants) | Placebo+ Abiraterone Acetate - Prednisolone | Apalutamide + Abiraterone Acetate - Prednisolone | Total |
|---|---|---|---|
| ARGENTINA | 3 | 3 | 6 |
| AUSTRALIA | 31 | 47 | 78 |
| BELGIUM | 16 | 16 | 32 |
| BRAZIL | 21 | 18 | 39 |
| CANADA | 12 | 18 | 30 |
| FRANCE | 18 | 16 | 34 |
| GERMANY | 10 | 9 | 19 |
| ITALY | 33 | 36 | 69 |
| JAPAN | 23 | 27 | 50 |
| MEXICO | 19 | 16 | 35 |
| NETHERLANDS | 14 | 16 | 30 |
| RUSSIAN FEDERATION | 59 | 46 | 105 |
| SOUTH AFRICA | 9 | 8 | 17 |
| SOUTH KOREA | 28 | 29 | 57 |
| SPAIN | 43 | 36 | 79 |
| UNITED KINGDOM | 23 | 27 | 50 |
| UNITED STATES | 128 | 124 | 252 |
Showing the first 100 of 173 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Mar 2018, 39 months.
Results were first posted in Aug 2021, 3 years 4 months after primary completion. A results delay was requested in Mar 2019.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 39 months is close to that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apalutamide
Aragon Pharmaceuticals, Inc. →